Sapio Sciences integrates NVIDIA BioNeMo to enhance AI-driven drug discovery
Sapio Sciences has announced the integration of NVIDIA’s BioNeMo platform into their Lab Informatics Platform, enabling researchers to leverage powerful AI capabilities directly within laboratory workflows for accelerated drug discovery and improved target selection accuracy through embedded computational tools.
AI-powered molecular modeling now accessible within unified workflow
The integration brings AI-driven computational drug discovery capabilities directly into the Sapio Electronic Lab Notebook (ELN), helping scientists streamline research processes. By incorporating NVIDIA BioNeMo’s capabilities, researchers can now access sophisticated in silico tools without navigating between multiple systems, enabling more rapid identification and optimisation of potential drug candidates.
Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, explained the rationale:
“AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA’s powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyze, and visualize both chemical and biological results.”
Key AI models integrated into research platform
The Sapio Platform now incorporates several powerful NVIDIA BioNeMo neural interface microservices (NIMs), including:
• AlphaFold2 NIM for accurate 3D protein structure prediction
• MoIMIM NIM to support small molecule design and optimisation
• DiffDock NIM, an AI-powered docking model developed by MIT
These tools enable scientists to generate novel candidate molecules early in the research process and test their interactions with target proteins through AI-driven molecular simulations.
Anthony Costa, Director, Digital Biology at NVIDIA, highlighted the significance: “Integrating BioNeMo into Sapio’s AI-driven research platform gives scientists access to advanced generative AI models for drug discovery. With AlphaFold2, MoIMIM, and DiffDock NIMs, researchers can predict, optimize, and validate drug candidates with greater speed and accuracy. This work underscores AI’s growing role in transforming pharmaceutical research and accelerating the path to breakthrough treatments.”
Science-aware informatics platform continues evolution
Sapio Sciences, which describes itself as a “science-aware” lab informatics platform, continues to develop its unified approach to laboratory data management. The company’s cloud-based solutions include Laboratory Information Management System (LIMS), Electronic Lab Notebook (ELN), and Scientific Data Management capabilities.
According to Cramer: “We are working with NVIDIA to equip scientists and researchers with the most advanced AI tools to drive innovation in life sciences. This collaboration is a major step toward making AI an integral part of the drug discovery process, helping researchers make faster, data-driven decisions and improve research outcomes.”
For more information, visit: https://bit.ly/4jbUs21
Digital issue: Please click here for more information
